Anastrozole is a selective non-steroidal aromatase inhibitor that blocks the conversion of androgens to estrogens in peripheral tissues. It is used as adjuvant therapy for early-stage hormone-sensitive breast cancer in postmenopausal women. Significant side effects of anastrozole include osteoporosis and increased levels of cholesterol. To date, seven case reports on anastrozole hepatotoxicity have been published. We report the case of an 81-year-old woman with a history of breast cancer, arterial hypertension, type 2 diabetes mellitus, hyperlipidemia, and chronic renal insufficiency. Four days after switching hormone therapy from tamoxifen to anastrozole, icterus developed along with a significant increase in liver enzymes (measured in the blood). The patient was admitted to hospital, where a differential diagnosis of jaundice was made and anastrozole was withdrawn. Subsequently, hepatic functions quickly normalized. The observed liver injury was attributed to anastrozole since other possible causes of jaundice were excluded. However, concomitant pharmacotherapy could have contributed to the development of jaundice and hepatotoxicity, after switching from tamoxifen to anastrozole since several the patient's medications were capable of inhibiting hepatobiliary transport of bilirubin, bile acids, and metabolized drugs through inhibition of ATP-binding cassette proteins. Telmisartan, tamoxifen, and metformin all block bile salt efflux pumps. The efflux function of multidrug resistance protein 2 is known to be reduced by telmisartan and tamoxifen and breast cancer resistance protein is known to be inhibited by telmisartan and amlodipine. Moreover, the activity of P-glycoprotein transporters are known to be decreased by telmisartan, amlodipine, gliquidone, as well as the previously administered tamoxifen. Finally, the role of genetic polymorphisms of cytochrome P450 enzymes and/or drug transporters cannot be ruled out since the patient was not tested for polymorphisms.

2nd Department of Internal Medicine University Hospital Královské Vinohrady and 3rd Faculty of Medicine Charles University Prague Czech Republic

3rd Faculty of Medicine Department of Pharmacology Charles University Prague Czech Republic and Faculty of Medicine Department of Pharmacology and Toxicology Charles University Pilsen Czech Republic

Erratum v

Ther Adv Chronic Dis. 2021 Apr 12;12:20406223211002790. doi: 10.1177/20406223211002790. PubMed

Zobrazit více v PubMed

Luellmann H, Mohr K, Hein L. (eds). Antiestrogen and antiprogestin active principles. In: Color atlas of pharmacology. 5th ed. Stuttgart, Germany: Thieme, 2018, pp.252–253.

Luellmann H, Mohr K, Hein L. (eds). Aromatase inhibitors. In: Color atlas of pharmacology. 5th ed. Stuttgart, Germany: Thieme, 2018, pp.254–255.

Hertz DL, Henry NL, Rae JM. Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients. Pharmacogenomics 2017; 18: 481–499. PubMed PMC

Wishart DS, Feunang YD, Guo AC, et al.. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 2018; 46: D1074-D1082. PubMed PMC

Anastrozole. In: Brayfield A. (ed.) Martindale: the complete drug reference. 39th ed. Pharmaceutical Press, 2017, pp.752–753.

Hilal-Dandan R, Brunton LL. (ed.). Natural products in cancer chemotherapy: hormones and related agents. In: Goodman and Gilman’s manual of pharmacology and therapeutics. 2nd ed. New York, NY: McGraw Hill Medical, 2014, pp.1080–1089.

Freiesleben SD, Furczyk K. A systematic review of agomelatine-induced liver injury. J Mol Psychiatry 2015; 3: 4. PubMed PMC

Shetty A, Cho W, Alazawi W, et al.. Methotrexate hepatotoxicity and the impact of nonalcoholic fatty liver disease. Am J Med Sci 2017; 354: 172–181. PubMed

Chalasani NP, Hayashi PH, Bonkovsky HL, et al.. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 2014; 109: 950–966; quiz 67. PubMed

Bunchorntavakul C, Reddy KR. Drug hepatotoxicity: newer agents. Clin Liver Dis 2017; 21: 115–134. PubMed

Alexander G. Chapter 34 - Liver and biliary tract. In: Bennett PN, Brown MJ, Sharma P. (eds) Clinical pharmacology. 11th ed. Oxford: Churchill Livingstone, 2012, pp.546–556.

DiPaola FW, Fontana RJ. Drug-induced liver injury. In: Dooley JS, Lok ASF, Garcia-Tsao G, et al.. (eds) Sherlock’s diseases of the liver and biliary system. Hoboken, NJ: John Wiley and Sons Ltd., 2018, pp.468–486.

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol 2019; 70: 1222–1261. PubMed

Hoofnagle JH, Bjornsson ES. Drug-induced liver injury - types and phenotypes. N Engl J Med 2019; 381: 264–273. PubMed

Rodrigues AD, Lai Y, Cvijic ME, et al.. Drug-induced perturbations of the bile acid pool, cholestasis, and hepatotoxicity: mechanistic considerations beyond the direct inhibition of the bile salt export pump. Drug Metab Dispos 2014; 42: 566–574. PubMed

Yang K, Kock K, Sedykh A, et al.. An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters. J Pharm Sci 2013; 102: 3037–3057. PubMed PMC

Lee WM, Dienstag JL. Toxic and drug-induced Hepatitis. In: Jameson JL, Fauci AS, Kasper DL, et al.. (eds) Harrison’s principles of internal medicine. 20th ed. New York, NY: McGraw-Hill Education, 2018.

Zapata E, Zubiaurre L, Bujanda L, et al.. Anastrozole-induced hepatotoxicity. Eur J Gastroenterol Hepatol 2006; 18: 1233–1234. PubMed

Lacey R, Evans A. An unusual cause of jaundice in a patient with breast cancer. BMJ Case Rep 2014; 2014: bcr2014205764. PubMed PMC

Islam MS, Wright G, Tanner P, et al.. A case of anastrazole-related drug-induced autoimmune hepatitis. Clin J Gastroenterol 2014; 7: 414–417. PubMed

Inno A, Basso M, Vecchio FM, et al.. Anastrozole-related acute hepatitis with autoimmune features: a case report. BMC Gastroenterol 2011; 11: 32. PubMed PMC

de la Cruz L, Romero-Vazquez J, Jimenez-Saenz M, et al.. Severe acute hepatitis in a patient treated with anastrozole. Lancet 2007; 369: 23–24. PubMed

Klapko O, Ghoulam E, Jakate S, et al.. Anastrozole-induced autoimmune hepatitis: a rare complication of breast cancer therapy. Anticancer Res 2017; 37: 4173–4176. PubMed

Xie C, Abdullah HMA, Abdallah M, et al.. Anastrozole-induced liver injury after a prolonged latency: a very rare complication of a commonly prescribed medication. BMJ Case Rep 2019; 12: e231741. PubMed PMC

Lin Y, Liu J, Zhang X, et al.. A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer. Cancer Sci 2014; 105: 1182–1188. PubMed PMC

Bruno S, Maisonneuve P, Castellana P, et al.. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 2005; 330: 932. PubMed PMC

Danan G, Teschke R. Drug-induced liver injury: why is the Roussel Uclaf Causality Assessment Method (RUCAM) still used 25 years after its launch? Drug Saf 2018; 41: 735–743. PubMed

Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–245. PubMed

Lewis JH. Chapter 10 - Drug-induced and toxic liver disease. In: Friedman LS, Martin P. (eds) Handbook of liver disease. 4th ed. Philadelphia: Elsevier, 2018, pp.130–157.

Chen M, Suzuki A, Borlak J, et al.. Drug-induced liver injury: interactions between drug properties and host factors. J Hepatol 2015; 63: 503–514. PubMed

Cuzick J, Sestak I, Baum M, et al.. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010; 11: 1135–1141. PubMed

Watkins PB. Idiosyncratic drug-induced liver injury in patients: detection, severity assessment, and regulatory implications. Adv Pharmacol 2019; 85: 165–193. PubMed

Konig J, Muller F, Fromm MF. Transporters and drug–drug interactions: important determinants of drug disposition and effects. Pharmacol Rev 2013; 65: 944–966. PubMed

Pedersen JM, Matsson P, Bergstrom CA, et al.. Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci 2013; 136: 328–343. PubMed PMC

Keppler D. The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia. Drug Metab Dispos 2014; 42: 561–565. PubMed

Weiss J, Sauer A, Divac N, et al.. Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos 2010; 31: 150–161. PubMed

Deferm N, De Vocht T, Qi B, et al.. Current insights in the complexities underlying drug-induced cholestasis. Crit Rev Toxicol 2019; 49: 520–548. PubMed

Correia MA. Drug biotransformation. In: Katzung BG. (ed.) Basic and clinical pharmacology. 13th ed. New York, NY: McGraw-Hill Education, 2015, pp.56–73.

Isaacs C, Wellstein A, Riedel AT. Hormones and related agents in the therapy of cancer. In: Brunton LL, Hilal-Dandan R, Knollmann BC. (eds) Goodman and Gilman’s: the pharmacological basis of therapeutics. 13th ed. New York, NY: Mc-Graw Hill Education, 2018, pp.1237–1247.

Giacomini KM, Sugiyama Y. Membrane transporters and drug response. In: Brunton LL, Hilal-Dandan R, Knollmann BC. (eds) Goodman and Gilman’s: the pharmacological basis of therapeutics. 13th ed. New York, NY: McGraw Hill Medical, 2018, pp.65–83.

Hu M, Lee HK, To KK, et al.. Telmisartan increases systemic exposure to rosuvastatin after single and multiple doses, and in vitro studies show telmisartan inhibits ABCG2-mediated transport of rosuvastatin. Eur J Clin Pharmacol 2016; 72: 1471–1478. PubMed

Yebyo HG, Aschmann HE, Kaufmann M, et al.. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: a systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. Am Heart J 2019; 210: 18–28. PubMed

Rosuvastatin. LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, 2012. PubMed

Shah J, Lingiah V, Pyrsopoulos N, et al.. Acute liver injury in a patient treated with Rosuvastatin: a rare adverse effect. Gastroenterology Res 2019; 12: 263–266. PubMed PMC

Devarbhavi H, Bonkovsky HL, Russo M, et al.. 56 - Drug-induced liver injury. In: Sanyal AJ, Boyer TD, Lindor KD, et al.. (eds) Zakim and Boyer’s hepatology. 7th ed. Philadelphia: Content Repository Only, 2018, pp.844–890.e17.

Meyer zu, Schwabedissen HE, Siegmund W, Kroemer HK, et al.. Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9*3 and ABCC2 -24C > T variants: a case report. BMC Res Notes 2014; 7: 688. PubMed PMC

Kock K, Ferslew BC, Netterberg I, et al.. Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4. Drug Metab Dispos 2014; 42: 665–674. PubMed PMC

Patel M, Taskar KS, Zamek-Gliszczynski MJ. Importance of hepatic transporters in clinical disposition of drugs and their metabolites. J Clin Pharmacol 2016; 56(Suppl. 7): S23–S39. PubMed

Corsini A, Bortolini M. Drug-induced liver injury: the role of drug metabolism and transport. J Clin Pharmacol 2013; 53: 463–474. PubMed

Garzel B, Zhang L, Huang SM, et al.. A change in bile flow: looking beyond transporter inhibition in the development of drug-induced cholestasis. Curr Drug Metab 2019; 20: 621–632. PubMed PMC

Morris ME, Morse BL. Membrane and drug transporters. In: Roche VF, Zito SW, Lemke T, et al.. (eds) Foye’s principles of medicinal chemistry. 8th ed. Wolters Kluwer, 2020, pp.131–154.

Gessner A, Konig J, Fromm MF. Clinical aspects of transporter-mediated drug–drug interactions. Clin Pharmacol Ther 2019; 105: 1386–1394. PubMed

Ivanyuk A, Livio F, Biollaz J, et al.. Renal drug transporters and drug interactions. Clin Pharmacokinet 2017; 56: 825–892. PubMed

Jansen PLM. Jaundice and cholestasis. In: Dooley JS, Lok ASF, Garcia-Tsao G, et al.. (eds) Sherlock’s diseases of the liver and biliary system. 13th ed. Hoboken, NJ: John Wiley and Sons Ltd., 2018, pp.231–251.

Fernández-Murga ML, Petrov PD, Conde I, et al.. Advances in drug-induced cholestasis: clinical perspectives, potential mechanisms and in vitro systems. Food Chem Toxicol 2018; 120: 196–212. PubMed

Schadt HS, Wolf A, Pognan F, et al.. Bile acids in drug induced liver injury: key players and surrogate markers. Clin Res Hepatol Gastroenterol 2016; 40: 257–266. PubMed